Docetaxel

DETAILS

Description:

Docetaxel Anhydrous is the anhydrous form of docetaxel, a semisynthetic side-chain analogue of paclitaxel with antineoplastic property. Docetaxel binds specifically to the beta-tubulin subunit of microtubules and thereby antagonizes the disassembly of the microtubule proteins. This results in the persistence of aberrant microtubule structures and results in cell-cycle arrest and subsequent cell death.

Docetaxel was patented in 1986 and approved for medical use in 1995. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.

Item Name	Docetaxel
CAS NO.	114977-28-5
Apparence	White Powder
Molecular Formula	C43H53NO14
Purity	99.5%
Advantage	OEM;ODM
Warranty	2 Years If Keep It Well
Certificate	GMP/ISO9001
Payment	Trade Assurance; L/C;T/T;Western Union

Application:

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel has an approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed.
Administered as a one-hour infusion every three weeks generally over a ten cycle course, docetaxel is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule agent.

1..It is a clinically well established anti mitotic chemotherapy medication (that is, it interferes with cell division).
2.It is used mainly for the treatment of breast, ovarian, and non-small cell lung cancer.
3.It has an FDA approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline based chemotherapy and failed to stop cancer progression or relapsed. An European approval docetaxel for use in hormone-refractory prostate cancer.
4.It is considered better than doxorubicin, paclitaxel and fluorouracil as a cytotoxic antimicrotubule

Certificate of Analysis

Batch Number		Z20190412001
Production Date		2019.04.12
Batch Quantity		80 KGS
Item	Test Standard		Testing Result
Appearance	Powder		Complies
Color	white Powder		Complies
Particle Size	100% pass 80 mesh		Complies
Oder	Characteristic		Complies
Taste	Characteristic		Complies
Loss on Drying	≤5.0%		2.20%
Residue on Ignition	≤0.1%		0.05%
Residual acetone	≤0.1%		Complies
Residual Ethanol	≤0.5%		Complies
Heave Mentals	≤10ppm		Complies
Na	≤0.1%		<0.1%
Pb	≤3 ppm		Complies
Total Plate	<1000CFU/g		Complies
Yeast & Mold	<100 CFU /g		Complies
E. Coli	Negative		Complies
Salmonella	Negative		Complies
Conclusion: Conform with USP Standard